Quality of Care: The Challenges, The Solutions

This symposium took place on the 29th September 2016 as a part of the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria

Chairperson: Kim Papp1
Speakers: Christos C. Zouboulis,2 Hilary Thomas3

1. K Papp Clinical Research and Probity Medical Research Inc., Waterloo, Ontario, Canada
2. Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany
3. KPMG, London, UK

Disclosure: Prof Papp has received honoraria for advisory boards and steering committee membership and provision of independent medical education, research grants, and consultancy fees from Gilead, Janssen, Kyowa Hakko Kirin, Leo, Lypanosys, Meiji Seika Pharma, MSD, Merck Serono, Mitsubishi Pharma, Mylan, Novartis, Pan Genetics, Pfizer, Regeneron, Roche, Sanofi-Aventis, Stiefel, Takeda UCB, Valeant, and Vertex. Prof Christos C. Zouboulis has received honoraria from AbbVie for participation on advisory boards, as a consultant, investigator, and speaker; his department received grants from AbbVie and Novartis for his participation as an investigator. Prof Hilary Thomas is KPMG’s Chief Medical Advisor and led the team which delivered the ‘Improvement in the management of Psoriatic Arthritis’ and ‘Guiding principles in Hidradenitis Suppurativa care’ reports.
Acknowledgements: Writing assistance was provided by Dr Steven Siak of ApotheCom, London, UK.
Support: The publication of this article was funded by AbbVie. The views and opinions expressed are those of the authors and not necessarily AbbVie. AbbVie was able to review the content of the manuscript for medical/scientific accuracy. AbbVie had no role in content development of the publication. All decisions regarding content were made by the authors.
Citation: EMJ Dermatol. 2016;4[1]:47-53.

Meeting Summary

Psoriatic arthritis (PsA) and hidradenitis suppurativa (HS) are both immune-mediated diseases with common cellular and cytokine pathways involved in their pathogenesis.1 Both are characterised by chronic and systemic inflammation and both involve elevated levels of the cytokines tumour necrosis factor-α (TNF-α), interleukin-17, and interleukin-23.1-5 PsA and HS are associated with substantial unmet needs and are sub-optimally managed. This educational session discussed ways to improve the quality of care and patient outcomes in PsA and HS.

Dr Kim Papp opened the symposium with an overview of the current unmet needs in PsA and HS and the key barriers to improving the management of both diseases. Prof Hilary Thomas discussed the Quantum initiative and how it could assist dermatologists in the treatment of PsA and HS. Dr Papp and Prof Christos C. Zouboulis then discussed the challenges of achieving optimal management in PsA and HS, as well as the solutions.

Download (PDF, 121KB)

Comments are closed.